Triple drug combination is promising option to treat metastatic HER2+ breast cancer

Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news161614658.html">Triple drug combination is promising option to treat metastatic HER2+ breast cancer</a></p> <p>Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options.</p>